Ειδήσεις: IMMUNOLOGY | PXAI

Version	Description	Date
8.42	[ADDED SOURCE REGISTRY LIST VIEW]	04/03/2026 16:19
8.41	[LOCALIZED INDEX.PHP MENU AND MODALS TO US ENGLISH]	04/03/2026 16:11
8.40	[TRANSLATED FRONTEND TO US ENGLISH]	04/03/2026 16:10
8.41	[RESTORED DETAILED SOURCES VIEW (ARTICLES + EVENTS) IN US ENGLISH]	04/03/2026 15:50
8.41	[RESTORED DETAILED SOURCES VIEW (ARTICLES + EVENTS) IN US ENGLISH]	04/03/2026 15:46
8.40	[REVERTED TO STANDARD TABLE LAYOUT (US ENGLISH)]	04/03/2026 15:40
8.39	[FIXED DB CONNECTION SCOPE IN SOURCES LOGIC]	04/03/2026 15:38
8.38	[TRANSLATED SOURCES VIEW TO US ENGLISH]	04/03/2026 15:01
8.37	[FULL FRONTEND TRANSLATION (MENU, FEED, COMMENTS, TTS) TO US ENGLISH.]	04/03/2026 14:58
8.67	[MANUAL OVERRIDE OF GREEK MENU ITEMS]	04/03/2026 13:36
8.66	[NGINX OPTIMIZED MENU FIX]	04/03/2026 13:33
8.65	[FIXED GREEK MENU ITEMS]	04/03/2026 13:32
8.60	[MENU & UI LOCALIZATION TO US ENGLISH]	04/03/2026 13:30
8.50	[FULL TRANSLATION TO US ENGLISH]	04/03/2026 13:27
9.75	[INJECTED EVENT FUSION_SUMMARY INTO FEED LOOPS TO DISPLAY AI TAGS CORRECTLY]	26/02/2026 14:44

31/03 14:47 statnews.com

STAT+: Biogen to acquire immunology biotech Apellis for $5.6 billion

Biogen Apellis acquisition immunology macular degeneration Syfovre

26/03 09:51 investing.com

Oxford BioMedica 2025 revenue rises 33%, sees second-half weighted 2026 growth

Oxford BioMedica revenue growth oncology immunology 2026 outlook biotech

25/03 16:57 yahoo.com

Merck to acquire Terns Pharmaceuticals for $6.7B

Merck Terns Pharmaceuticals acquisition oncology immunology $6.7B

24/03 15:26 statnews.com

STAT+: Gilead to acquire immunology biotech, offers lifeline to Galapagos

Gilead immunology biotech drug pricing Trump U.S. healthcare foreign pricing

24/03 00:37 investing.com

Gilead to buy biotech firm Ouro Medicines in over $2 billion deal

Gilead Sciences Ouro Medicines acquisition biotech $2B oncology

19/03 18:41 newsweek.com

An Organ Was Long Dismissed as 'Irrelevant' for Adults—This May Soon Change

thymus cancer therapy adult immunity organ re-evaluation medical breakthrough immunology

19/03 07:03 defenseworld.net

Biogen Conference: Tau ASO CELIA Updates, Pre-Symptomatic Leqembi, SMA Phase 3 Plans

Biogen tau ASO Alzheimer’s disease SMA Leqembi immunology

17/03 08:03 defenseworld.net

Enanta Pharmaceuticals Pitches RSV Phase 3 Plans, Expands Oral Immunology Pipeline at Citizens Conference

Enanta RSV small‑molecule immunology hepatitis C VIEKIRA PAK

17/03 08:03 defenseworld.net

Enanta Pharmaceuticals Pitches RSV Phase 3 Plans, Expands Oral Immunology Pipeline at Citizens Conference

Enanta RSV small‑molecule immunology hepatitis C VIEKIRA PAK

Loading...